Michael V. Gormally

668 total citations
18 papers, 418 citations indexed

About

Michael V. Gormally is a scholar working on Molecular Biology, Oncology and Infectious Diseases. According to data from OpenAlex, Michael V. Gormally has authored 18 papers receiving a total of 418 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 5 papers in Oncology and 2 papers in Infectious Diseases. Recurrent topics in Michael V. Gormally's work include CAR-T cell therapy research (4 papers), FOXO transcription factor regulation (4 papers) and Protein Degradation and Inhibitors (3 papers). Michael V. Gormally is often cited by papers focused on CAR-T cell therapy research (4 papers), FOXO transcription factor regulation (4 papers) and Protein Degradation and Inhibitors (3 papers). Michael V. Gormally collaborates with scholars based in United States, United Kingdom and Singapore. Michael V. Gormally's co-authors include Shankar Balasubramanian, Giovanni Marsico, Deborah A. Sanders, Malkiat S. Johal, Sam Michael, Ganesha Rai, Christopher Lowe, Ajit Jadhav, Dijana Matak‐Vinković and Thomas S. Dexheimer and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Blood.

In The Last Decade

Michael V. Gormally

18 papers receiving 417 citations

Peers

Michael V. Gormally
Roy B. Lefkowitz United States
Megan L. Choy United States
Timothy J. Eisen United States
Charles H. Adelmann United States
Ellen V. Stevens United States
Michael V. Gormally
Citations per year, relative to Michael V. Gormally Michael V. Gormally (= 1×) peers Paula Díez

Countries citing papers authored by Michael V. Gormally

Since Specialization
Citations

This map shows the geographic impact of Michael V. Gormally's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael V. Gormally with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael V. Gormally more than expected).

Fields of papers citing papers by Michael V. Gormally

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael V. Gormally. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael V. Gormally. The network helps show where Michael V. Gormally may publish in the future.

Co-authorship network of co-authors of Michael V. Gormally

This figure shows the co-authorship network connecting the top 25 collaborators of Michael V. Gormally. A scholar is included among the top collaborators of Michael V. Gormally based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael V. Gormally. Michael V. Gormally is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Cohen, Tal, Paul Zumbo, Michael V. Gormally, et al.. (2025). Enhancing the Persistence and Anti-Tumor Efficacy of CAR-T and CAR-NK Cells through Genetic Disruption of Death Receptors. Transplantation and Cellular Therapy. 31(2). S1–S1. 1 indexed citations
2.
Sewastianik, Tomasz, Michael V. Gormally, Patrick J. Halvey, et al.. (2025). Allele-specific HLA LOH in solid tumors: distinct patterns by tumor type and potential prognostic relevance. Journal for ImmunoTherapy of Cancer. 13(9). e012435–e012435. 1 indexed citations
3.
Cohen, Tal, Paul Zumbo, Michael V. Gormally, et al.. (2024). Abstract 40: Persistence but not antitumor efficacy of CAR-engineered lymphocytes is governed by a FAS/FAS ligand auto-regulatory circuit. Cancer Research. 84(6_Supplement). 40–40. 1 indexed citations
4.
Gormally, Michael V., Matteo Repetto, Justin Jee, et al.. (2024). A pan-cancer analysis of SMARCA4 alterations and the unique clinicogenomic characteristics associated with SMARCA4 mutation types.. Journal of Clinical Oncology. 42(16_suppl). 3073–3073. 1 indexed citations
5.
Briggs, Neima, Michael V. Gormally, Fangyong Li, et al.. (2021). Early but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19. PLoS ONE. 16(7). e0254453–e0254453. 20 indexed citations
6.
Gormally, Michael V., Neima Briggs, Muyi Li, et al.. (2020). Use of Convalescent Plasma Therapy in Severe Coronavirus Disease 2019: The Yale-New Haven Health System Experience. Blood. 136(Supplement 1). 39–40. 2 indexed citations
7.
Heske, Christine M., Mindy I. Davis, Joshua T. Baumgart, et al.. (2017). Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clinical Cancer Research. 23(23). 7301–7311. 50 indexed citations
8.
Cording, Amy, Michael V. Gormally, Peter J. Bond, et al.. (2016). Selective inhibitors of trypanosomal uridylyl transferase RET1 establish druggability of RNA post-transcriptional modifications. RNA Biology. 14(5). 611–619. 6 indexed citations
9.
Gormally, Michael V., Giovanni Marsico, Ganesha Rai, et al.. (2016). Abstract 3088: Transcription factor as target: Novel small molecule inhibits FOXM1 DNA binding and oncogenic gene products. Cancer Research. 76(14_Supplement). 3088–3088. 1 indexed citations
10.
Sanders, Deborah A., Michael V. Gormally, Giovanni Marsico, et al.. (2015). FOXM1 binds directly to non-consensus sequences in the human genome. Genome Biology. 16(1). 130–130. 49 indexed citations
11.
Fung, Juan José, Alan Kosaka, Xiaochuan Shan, et al.. (2015). Registered report: Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukemia. eLife. 4. 8 indexed citations
12.
Marsico, Giovanni & Michael V. Gormally. (2014). Small molecule inhibition of FOXM1: How to bring a novel compound into genomic context. Genomics Data. 3. 19–23. 10 indexed citations
13.
Gormally, Michael V., Thomas S. Dexheimer, Giovanni Marsico, et al.. (2014). Suppression of the FOXM1 transcriptional programme via novel small molecule inhibition. Nature Communications. 5(1). 5165–5165. 168 indexed citations
14.
Gormally, Michael V., et al.. (2013). Light-mediated in cell downregulation of G-quadruplex-containing genes using a photo-caged ligand. Chemical Communications. 49(76). 8453–8453. 36 indexed citations
15.
Zwang, Theodore J., Michael V. Gormally, Malkiat S. Johal, & Matthew H. Sazinsky. (2011). Enhanced iron availability by protein glycation may explain higher infection rates in diabetics. BioMetals. 25(1). 237–245. 7 indexed citations
16.
Dixon, Matthew C., et al.. (2009). Real-Time Characterization of Polymer Film Degradation with Quartz Crystal Microbalance with Dissipation Monitoring. TechConnect Briefs. 1(2009). 364–367. 1 indexed citations
17.
Gormally, Michael V., et al.. (2009). Controlling Tyrosinase Activity on Charged Polyelectrolyte Surfaces: A QCM-D Analysis. Langmuir. 25(17). 10014–10019. 20 indexed citations
18.
Lane, Thomas J., et al.. (2008). Dual-Beam Polarization Interferometry Resolves Mechanistic Aspects of Polyelectrolyte Adsorption. Langmuir. 24(19). 10633–10636. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026